-
SAMHSA’s Final Rule on MOUD Published
In February of this year, SAMHSA published a final rule allowing for the flexible use of medications to treat opioid use disorder in Opioid Treatment Programs that were enacted during the COVID-19 pandemic to become permanent. Highlights of this modification include: This rule (89 FR 7528) became effective on April 2, 2024, and providers need to be in compliance by October 2, 2024. The specifics and further details can be found on the Federal Register website.
-
Virtual Xylazine Discussion Forum for CTN Investigators: September 26, 4pm ET
Join the Center for the Clinical Trials Network (CCTN) on Tuesday, September 26, 2023 from 4:00-5:30pm ET for a virtual Xylazine Discussion Forum for CTN investigators. Speakers Jeanmarie Perrone, MD (University of Pennsylvania) and Rachel Haroz, MD (Cooper University and Rowan University) will highlight the emerging threat of xylazine in the U.S. illicit drug supply, summarize emerging practices for treating people taking xylazine-adulterated opioids, and discuss research gaps and opportunities identified in a recent meeting of experts convened by NIDA. CTN researchers will be encouraged to participate in discussion and Q&A. View the recordings from this event here! Posted August 14, 2023, Updated September 2023
